Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NEW YORK, Nov. 08, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of InfuSystem Holdings, Inc. (“InfuSystem” or “the Company”) (NYSE:INFU) between May 12, 2015 and November 7, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/infusystem-holdings
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period InfuSystem made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal control over financial reporting; (2) InfuSystem’s financial statements dating back to the beginning of 2015 overstated the estimated accounts receivable collections, which in turn overstated revenues and pre-tax income by a corresponding amount; (3) InfuSystem’s financial statements dating back to the beginning of 2015 could no longer be relied upon; and (4) as a result of the foregoing, InfuSystem’s financial statements were materially false and misleading at all relevant times.
If you suffered a loss in InfuSystem you have until January 9, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
